scholarly journals Novel 9-(alkylthio)-Acenaphtho[1,2-e]-1,2,4-triazine derivatives: synthesis, cytotoxic activity and molecular docking studies on B-cell lymphoma 2 (Bcl-2)

Author(s):  
Mohammad K Mohammadi ◽  
Omidreza Firuzi ◽  
Mehdi Khoshneviszadeh ◽  
Nima Razzaghi-Asl ◽  
Saghi Sepehri ◽  
...  
Author(s):  
Mehad Mustafa Adam Khamiss; Khamiss ◽  
Prakash C. Choudhary

This article deals with anticancer studies of phytochemicals identified from Solenostemma Argel leaf extract using GC-MS analysis and molecular docking studies. B cell lymphoma-2 (BCL-2) agonists are useful for regulating apoptosis which is essential for several cancers. The aim of the present study is to investigate the BCl-2 agonist property of phytochemicals from the extract of S. Argel using an Insilco approach. The docking on human BCL-2 protein was determined by GOLD 3.0.1 software. It is concluded from the studies that compound suggested by GCMS at RT 17.1 minute is 4,5,7-trihydroxy isoflavone showed best result with highest fitness index


2019 ◽  
Vol 28 (8) ◽  
pp. 1132-1160 ◽  
Author(s):  
Zabiulla Zabiulla ◽  
Vikas H. Malojirao ◽  
Yasser Hussein Eissa Mohammed ◽  
Prabhu Thirusangu ◽  
B. T. Prabhakar ◽  
...  

2020 ◽  
Vol 1220 ◽  
pp. 128687
Author(s):  
Vikrant Patil ◽  
Anurag Noonikara-Poyil ◽  
Shrinivas D. Joshi ◽  
Shivaputra A. Patil ◽  
Siddappa A. Patil ◽  
...  

Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4912-4912
Author(s):  
Kazumi Hagiwara ◽  
Yuki Kojima ◽  
Yasuhiko Miyata ◽  
Hirokazu Nagai

Abstract Abstract 4912 Bendamustine, a kind of alkylating agent, has demonstrated a favorable anti-tumor activity both alone and in combination with rituximab in low grade B cell lymphoma. Because the kinase cascades, including B-cell receptor signaling, are necessary for the proliferation and survival of the lymphoma cells, the kinase inhibitors have been developed as molecular target agents of malignant lymphomas. We investigated the cytotoxic effect of bendamustine, both as a single agent and in combination with these new kinase inhibitors in human lymphoid cell lines. We used three B-cell lines, BALL-1 (acute lymphoblastic leukemia), SKLY16 (B-cell lymphoma) and DHL4 (diffuse large B cell lymphoma), and T-cell line THP-6 in this study. These cells were treated with bendamustine alone or combined with enzastaurin (a PKC-β inhibitor), CAL-101 (a p110δ PI3K inhibitor), PCI-32765 (a Btk inhibitor) or R406 (a Syk inhibitor) for 48 hours. Drug-induced cytotoxicity was evaluated using the MTT assay. Cell viability in each experiment was normalized using untreated controls. The treatment with bendamustine alone decreased cell viability in a dose-dependent manner on these three B-cell lines. In contrast, T-cell line THP-6 showed the resistance to bendamusitine. For the combination study, cells were exposed to bendamustine (10μM) and one of these kinase inhibitors at various concentrations simultaneously for 48 hours. CAL-101 and PCI-32765 did not enhance the cytotoxic effect on all of B-cell lines. In BALL-1 and SKLY16 cells, the combination with enzastaurin or R406 resulted in a higher cytotoxic activity than that induced by bendamustine alone. In DHL4 cells, the treatment combined with R406 inhibited cell growth effectively, but not with enzastaurin. To evaluate whether these drug combinations are synergistic, a combination index (CI) was calculated and normalized isobolograms were constructed from non-constant ratio drug combinations using Calcusyn software. The CI values were less than 0. 7 in SKLY16 cells treated with bendamustine and enzastaurin, indicating that these produced synergistic cytotoxic effects in cell line-dependent manner. Our results show that enzastaurin might potentiate the cytotoxic activity of bendamustine in vitro and be a good candidate for the combination with bendamustine. Disclosures: No relevant conflicts of interest to declare.


2013 ◽  
Vol 4 (1) ◽  
pp. 14 ◽  
Author(s):  
G Kathiravan ◽  
V Bhuvaneshwari ◽  
Evelin Kramony ◽  
SripathiM Sureban ◽  
HarshaN Sree

2021 ◽  
Vol 10 (4) ◽  
pp. 443-458
Author(s):  
Rehab Fikry Taher ◽  
Ahmed A. Al-Karmalawy ◽  
Ahmed I. Abd El Maksoud ◽  
Hany Khalil ◽  
Amr Hassan ◽  
...  

Introduction: Hymenosporum flavum (Hook.) F. Muell. is the sole species within the genus Hymenosporum is known for its antimicrobial activity. The current study aims to examine the prospective activity of H. flavum as a safe supporter of sorafenib (as a reference standard) against hepatocellular carcinoma (HCC). Methods: Isolation and identification of compounds were made by chromatographic and spectroscopic methods. A fingerprint for the plant extract was done using HPLC-MS/MS spectrometric analysis. The total plant extract was examined in vitro for HCC activity. The isolated flavonoids were examined for their cytotoxic activities using molecular docking studies against both RAF-1 and ERK-2, and the promising compounds were further examined in vitro using quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Results: Two new flavonols were isolated from the leaf extract of H. flavum (Hook.) F. Muell., quercetin-3-O-(glucopyranosyl 1→2 ribopyranoside) (1) and kaempferol-3-O-(glucopyranosyl 1→2 ribopyranoside) (2), accompanying other six known flavonoids (3-8), and identified via spectroscopic analysis. Moreover, HPLC- PDA/MS/MS spectrometric analysis revealed the presence of seventy phenolic metabolites. The cytotoxic activity of the plant extract confirmed its potential action on HepG2 cells indicated by the production level of lactate dehydrogenase (LDH) upon treatment compared with the normal cells. The isolated flavonoids were examined for their cytotoxic activity using molecular docking studies against both RAF-1 and ERK-2 as proposed mechanisms of their anticancer activities. Furthermore, compounds 1 and 3, which showed the best in silico results, were further examined in vitro using qRT-PCR. They exhibited promising inhibitory activities against both RAF-1 and ERK-2 gene expression. Moreover, they showed promising cytotoxic activities indicated by the MTT assay. Also, both of them improved the efficiency of sorafenib in targeting both RAF-1 and ERK-2 pathways suggesting synergistic combinations. Conclusion: Our findings showed the potential cytotoxic activity of H. flavum extract on HepG2 cells. Some isolated compounds (1 & 3) exhibited promising inhibitory activities against both RAF-1 and ERK-2 gene expression giving a lead future study for these compounds to be used in pharmaceutical preparations either alone or in combination with sorafenib.


2020 ◽  
Author(s):  
Sandeep Kumar Kushwaha ◽  
Veerbhan Kesarwani ◽  
Samraggi Choudhury ◽  
Sonu Gandhi ◽  
Shailesh Sharma

AbstractSARS-CoV-2 is a single-stranded RNA virus that has caused more than 0.29 million deaths worldwide as of May 2020, and influence of COVID-19 pandemic is increasing continuously in the absence of approved vaccine and drug. Moreover, very limited information is available about SARS-CoV-2 expressed regions and immune responses. In this paper an effort has been made, to facilitate vaccine development by proposing multiple epitopes as potential vaccine candidates by utilising SARS-CoV-2 transcriptome data. Here, publicly available RNA-seq data of SARS-CoV-2 infection in NHBE and A549 human cell lines were used to construct SARS-CoV-2 transcriptome to understand disease pathogenesis and immune responses. In the first step, epitope prediction, MHC class I and II gene identification for epitopes, population coverage, antigenicity, immunogenicity, conservation and crossreactivity analysis with host antigens were performed by using SARS-CoV-2 transcriptome, and in the second step, structural compatibility of identified T-and B-cell epitopes were evaluated with MHC molecules and B-cell receptors through molecular docking studies. Quantification of MHC gene expression was also performed that indicated high variation in allele types and expression level of MHC genes with respect to cell lines. In A549 cell line, HLA-A*30:01:01:01 and HLA-B*44:03:01:01 were highly expressed, whereas 92 variants of HLA-A*24 genes such as HLA-A*24:02:01:01, HLA-A*24:286, HLA-A*24:479Q, HLA-A*24:02:134 and HLA-A*24:02:116 were highly expressed in NHBE cell lines. Prevalence of HLA-A*24 alleles was suggested as risk factors for H1N1 infection, and associated with type-1 diabetes. HLA-C*03:03, linked with male infertility factors was also highly expressed in SARS-CoV-2 infected NHBE cell lines. Finally, three potential T-cell and five B-cell epitopes were selected for molecular docking studies with twenty-two MHC molecules and two B-cell receptors respectively. The results of in silico analysis indicated that proposed epitopes have high potential to recognize immune response of SARS-CoV-2 infection. This study will facilitate in vitro and in vivo vaccine related research studies.


Sign in / Sign up

Export Citation Format

Share Document